TipRanks
Advertisement
Advertisement
Tyler Van Buren Reiterates Buy on Oruka Therapeutics Citing Superior PASI 100 Data, Upcoming Durability Readouts, and Accelerated Pipeline Timelines
PremiumRatingsTyler Van Buren Reiterates Buy on Oruka Therapeutics Citing Superior PASI 100 Data, Upcoming Durability Readouts, and Accelerated Pipeline Timelines
2M ago
Oruka Therapeutics Appoints Todd Edwards Chief Commercial Officer
Premium
Company Announcements
Oruka Therapeutics Appoints Todd Edwards Chief Commercial Officer
2M ago
Oruka Therapeutics appoints Todd Edwards as chief commercial officer
Premium
The Fly
Oruka Therapeutics appoints Todd Edwards as chief commercial officer
2M ago
Oruka: Differentiated IL-23 Profile and Solid Cash Runway Support Maintained Buy Rating and Unchanged $125 Price Target
PremiumRatingsOruka: Differentiated IL-23 Profile and Solid Cash Runway Support Maintained Buy Rating and Unchanged $125 Price Target
3M ago
3 Healthcare Stocks with Strong Upside to Consider in July 2026, According to Analysts
Premium
Market News
3 Healthcare Stocks with Strong Upside to Consider in July 2026, According to Analysts
3M ago
Oruka Therapeutics falls -8.1%
Premium
The Fly
Oruka Therapeutics falls -8.1%
3M ago
Oruka Therapeutics Expands IL-23 License, Adds Dosing Limits
PremiumCompany AnnouncementsOruka Therapeutics Expands IL-23 License, Adds Dosing Limits
5M ago
Oruka: Strong ORKA-001 Clinical Profile and Pipeline Momentum Support Reiterated Buy Rating and Unchanged $120 Price Target
Premium
Ratings
Oruka: Strong ORKA-001 Clinical Profile and Pipeline Momentum Support Reiterated Buy Rating and Unchanged $120 Price Target
5M ago
Julian Harrison Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target on Strong Clinical Profile and Cash Position
Premium
Ratings
Julian Harrison Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target on Strong Clinical Profile and Cash Position
5M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―